Answers are grounded in this paper and cite their sources.
Experimental treatment reduced ischemia-reperfusion injury in DCD kidneys, suggesting potential improvements in transplant success.
Kidney transplantation serves as an ideal treatment for patients with end-stage renal disease. Due to the organ shortage, there has been an uptick in the use of circulatory death donors (DCD), yet DCD kidneys endure severe ischemia-reperfusion injury (IRI), limiting transplantation efficacy. Therefore, we developed a strategy combining hypothermic machine perfusion (HMP) with aldehyde dehydrogenase 2 (ALDH2) agonist Alda-1, using quaternized chitosan/5β-cholanic acid/Alda-1 nanoparticles (A-NCH) for ex vivo DCD kidney repair. Methodologically, A-NCH was synthesized by conjugating O-hydroxypropyl trimethylammonium chloride chitosan (O-HTCC) with 5β-cholanic acid via EDC/NHS-mediated coupling, forming self-assembled micelles with a mean diameter of 132.4 ± 0.3 nm and ζ-potential of 45.0 ± 1.0 mV. It exhibited a high drug loading ratio (41.9%), with 80% of Alda-1 released at 4 °C within 3.5 h following the Weibull model, enabling sustained drug delivery during HMP. A-NCH demonstrated outstanding compatibility with cells and blood, as well as effective antibacterial properties combat Escherichia coli and Staphylococcus aureus. In vitro, A-NCH reduced H2O2- and oxygen-glucose deprivation- and -reoxygenation-induced oxidative stress and apoptosis in HK-2 and HUVECs. In vivo, using a rat DCD kidney transplantation model, A-NCH-administered HMP accelerated kidney graft function recovery and alleviated renal tubular injury. Mechanistically, A-NCH activated ALDH2, inhibited the P38 MAPK pathway, promoted nuclear translocation of TEAD4/YAP1, and suppressed the transition of proximal tubule cells to an injured phenotype. In this study, the solubility and drug loading of Alda-1 were improved by 5β-cholanic acid modification of O-HTCC, which proved the synergistic efficacy with HMP in DCD kidney repair and provided a translatable strategy to expand the donor pool.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: